Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
نویسندگان
چکیده
منابع مشابه
P01-027 – Normal HRV in colchicine-resistant FMF patients
Introduction The relationship between autonomic nervous system (ANS) dysfunction and familial Mediterranean fever (FMF) is controversial. Heart rate variability (HRV) is a powerful, simple and reliable technique for the evaluation of ANS dysfunction. Recently, we reported on normal HRV parameters, suggestive of normal ANS function, in patients with uncomplicated FMF. Also, we reported on an ass...
متن کاملPW01-007 – Colchicine brand switching in FMF patients
Introduction In July of 2009 the U.S. Food and Drug Administration enacted new regulation of colchicine under the “Unapproved Drugs Program.” Like other old drugs that were on the market before the existence of the FDA, colchicine had never been subjected to FDA-required safety and efficacy trials. One company elected to put colchicine through the FDA’s approval protocol and when approval was g...
متن کاملColchicine therapy in children with FMF
Results Colchicine dose correlates with the genotype. It further increases linearly with an increase of age (1 18 years), body weight and body surface area. The correlation of colchicine dose with body surface revealed an average of 1 mg colchicine / 1 m. A high response rate in the CRP and the attack rate is shown both at time of therapy introduction (70% response CRP: 45.5% / attack frequency...
متن کاملPW01-005 – Effects of placebo and colchicine on FMF patients
Results A total amount of 50 patients (22 girls, 28 boys) were included. The median age of the patients was 8.5 years (2.5-17.5). 78% of the patients suffered from fever attacks suggestive of FMF every 1-4 weeks. The attack interval of the remaining patients was more than one month. At the time of admission, the median values for ESR and CRP were; 24.5 mm/hr (1-100) and 2 mg/dl (0-31), respecti...
متن کاملP01-031 – Anakinra for colchicine resistant FMF
Methods We plan to include patients, agreeing with clinical and genetic diagnosis of FMF, who suffer from FMF attacks, at least once per month, in one of the sites commonly involved by FMF (Chest, abdomen, lower extremity large joints, and skin), despite treatment with colchicine 2 mg/ day or less (in case of colchicine intolerance). Involvement with other diseases relevant (vasculitis, spondyl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Case Reports in Rheumatology
سال: 2019
ISSN: 2090-6889,2090-6897
DOI: 10.1155/2019/2716127